Hubrecht Organoid Technology and GlaxoSmithKline will together develop a human relevant Lung and Colon Immuno-Oncology model using Tumor Organoids, to better predict drug effectiveness for small molecule therapies.
Atherosclerosis is the main underlying cause of cardiovascular disease (CVD) and due to its multifactorial natural is often studied in animal models. Here the aim is to develop an innovative ex vivo system to study the atherosclerotic disease process based on the actual human atherosclerotic plaque. In line with the Transition to Animal-free Innovation (TPI), the aim is to develop a model that generates data on the effect of novel drugs that is highly translatable to the effect of the novel drug in the cardiovascular patient, while at the same time minimising the number of laboratory animals used. Moreover, the aim is to utilise this model to discover new biomarkers of successful treatment, which could expedite the transition of CVD therapeutic into clinical trial.
The RBD‐CURE project will develop innovative gene therapy approaches for patients with rare bleeding disorders. The unique expertise of Sanquin on bleeding disorders together with the advanced gene therapy strategies developed by SanaGen and the Netherlands Institute for Neurosciences aims to provide a permanent cure for patients with rare bleeding disorders.
Hepatocellular carcinoma is the most frequent liver malignancy and the fourth most common cause of cancer-related death worldwide. There is a clear clinical need for accessible and reliable parameters to identify high-risk populations in order to decrease the high mortality rates of hepatocellular carcinoma.
Worldwide, venomous snakebites claim about 125.000 deaths and maim 450.000 people yearly, mostly in poor rural areas, for which there is no safe and adequate treatment. This situation will be alleviated by developing human antibodies which will be safe and much better than the current treatments.
To help in the battle against COVID-19, a novel compact CT scanner will be developed to rapidly screen for disease patterns and monitor disease progression. This is done by developing a new type of compact mobile CT scanner, equipped with artificial intelligence software to detect disease patterns accurately.
The knowledge is missing that is essential for cost-effective roll-out of personalised treatment of insomnia. This project solves the bottleneck by creating a research platform for combined online behavioural change intervention and long-term monitoring of sleep, traits and health. A growing database will allow for optimised sleep interventions tailor to personalised needs, capacities, limitations and estimated benefits.
In muscle diseases, muscle fibers lose their capacity to contract, resulting in loss of mobility and respiration. In this project advanced 3D models of muscle diseases in vitro will be generated and the effects will be investigated on the smallest contractile unit present in muscle cells using highly sensitive force measurements.
The immune system has potent mechanisms with which it deals with intruding viruses, bacteria and tumors, protecting us from disease. However, tumors contain mutations leading to resistance to the immune system. The NextIO project aims to develop a medicine that restores the sensitivity of the cancer to the immune system.
Acute myeloid leukemia (AML) is a form of blood cancer that is still difficult to cure and better therapies against AML are clearly needed. As a continuation of a long-standing collaboration between the Schuringa lab at the UMCG and Janssen will exploit potential novel targets against leukemic stem cells.